Prozac rival makes you happy and sexy ... but sleepy and fat
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A rival for the sunshine drug, Prozac, the fastest selling antidepressant in history, is to be launched next week, with claims that it is the most powerful mood-lifter yet discovered.
A powerful selling point of the new drug, to be sold under the brand name Zispin, is likely to be the absence of sexual side effects. Prozac, like most anti-depressants, causes anorgasmia - difficulty in achieving orgasm.
However, a drawback of Zispin (chemical name, mirtazapine) is that it also causes weight gain in some patients, in contrast to the weight loss associated with Prozac, and has a temporary sedative effect.
The new drug is a novel pharmaceutical compound that acts in a different way from Prozac and is claimed to be 40 per cent more effective in overcoming depression. It targets two neurotransmitters (brain chemicals), noradrenaline and serotonin, which are believed to be linked to depression, compared with the one, serotonin, influenced by Prozac (medical name, fluoxetine).
A six-week trial of Zispin in 140 patients, half of whom took the drug while the other half took Prozac, found that the mood of those on Zispin improved more rapidly and to a greater extent, as measured by a standard depression questionnaire, than those on Prozac.
Professor Chris Thompson, consultant psychiatrist at the Royal South Hants Hospital, Southampton, said the speed of improvement of patients on the new drug was astonishing. "It is unprecedented that a new antidepressant should provide an increase of efficacy of some 40 per cent over the market leader, fluoxetine." He said the most important issues were to replicate the findings and to get longer-term data.
Zispin is the first NaSSA - a Noradrenergic and Specific Serotonergic Antidepressant - acting on the two neurotransmitters, noradrenaline and serotonin, in contrast to the SSRI's - Selective Serotonin Re-uptake Inhibitors - such as fluoxetine, Prozac, which only influence serotonin. The manufacturers of Zispin, Organon Laboratories, claim this is why it is more powerful but has fewer side effects.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments